Search clinical trials for: Irbesartan / Amlodipine

Total 706 results

Sanofi

Completed

Study of Efficacy and Safety of Irbesartan/Amlodipine 4 Fixed Combination Therapy in Hypertensive Patients Uncontrolled on Irbesartan or Amlodipine Monotherapy

Hypertension

Russian Federation
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Sanofi

Completed

Irbesartan and Amlodipine Combination in Controlling Blood Pressure (I-COMBO)

Hypertension

India, Philippines, Taiwan, Korea, Republic of
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Irbesartan 150 mg Monotherapy (I-ADD)

Hypertension

Morocco, Brazil, Colombia, Guatemala, Mexico, Tunisia, United Arab Emirates, Venezuela
Handok Inc.

Completed

Pharmacokinetics of Irbesartan High/Amlodipine FDC and Co-administration of Irbesartan High and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Sanofi

Completed

Irbesartan/Amlodipine in Hypertensive Patients Uncontrolled on Amlodipine 5 mg Monotherapy (I-COMBINE)

Hypertension

Brazil, Chile, Colombia, Egypt, Lebanon, Mexico, Morocco, Tunisia, Venezuela
Handok Inc.

Completed

Pharmacokinetics of Irbesartan/Amlodipine High FDC and Co-administration of Irbesartan and Amlodipine High in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients

Essential Hypertension

Korea, Republic of
Handok Inc.

Completed

Pharmacokinetics of Irbesartan/Amlodipine FDC and Co-administration of Irbesartan and Amlodipine in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Handok Inc.

Completed

Phase 2 Study to Evaluate the Efficacy and Safety of Irbesartan and Amlodipine Combined or Alone in Patients With Essential Hypetension

Essential Hypertension

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Completed

PHARES Study: Management of Resistant Hypertension

Hypertension

France
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Two Irbesartan in Healthy Chinese Subjects

Therapeutic Equivalency

China
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension

Hypertension

Korea, Republic of
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy as First Line Treatment for Severe Hypertension

Hypertension

United States, Belgium, Canada, Germany, Russian Federation, France, Israel, Netherlands
Chong Kun Dang Pharmaceutical
Severance Hospital

Completed

Drug-drug Interaction Study(CKD-501, Amlodipine)

Type 2 Diabetes Mellitus

Korea, Republic of
LanZhou University

Unknown

Combined Antihypertensive Therapy and Sexual Dysfunction

Hypertension | Sexual Dysfunction

China
Sanofi
Bristol-Myers Squibb

Completed

The Efficacy and Safety of Irbesartan 150/12.5 mg and 300/25 mg in Patients With Mild Hypertension

Hypertension

United States
Steno Diabetes Center Copenhagen

Completed

Optimal Dose of Irbesartan for Renoprotection in Type 2 Diabetic Patients With Persistent Microalbuminuria

Type 2 Diabetes | Microalbuminuria

Denmark
Zhi-Hong Liu, M.D.

Terminated

A Prospective, Single-center, Randomized, Controlled Study of Sevelamer Carbonate in the Lipid Metabolism and Uric Acid Treatment of Obesity-Related Glomerulopathy

Obesity and Glomerulopathy

China
Travere Therapeutics, Inc.

Active, not recruiting

A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT)

Immunoglobulin A Nephropathy

United States, Australia, Belgium, Croatia, Czechia, Estonia, France, Germany, Hong Kong, Italy, Korea, Republic of, Lithuania, New Zealand, Poland, Portugal, Spain, Taiwan, United Kingdom
Steno Diabetes Center Copenhagen
Bristol-Myers Squibb; Sanofi-Synthelabo

Completed

Irbesartan in Type 2 Diabetes

Hypertension | Type 2 Diabetes | Microalbuminuria
Damanhour University

Completed

Drug Interaction Between Irbesartan and Hydrochlorothiazide

Healthy

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I SELECT - Irbesartan In Hypertensive Patients With Left Ventricular Hypertrophy

Hypertension

Egypt
Jiangsu Famous Medical Technology Co., Ltd.

Unknown

Clinical Trial of HuangKui Capsule to Treat Diabetic Kidney Disease

Diabetic Kidney Disease

China
University of Southern Denmark
Bristol-Myers Squibb

Completed

Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study)

Myocardial Infarction

Denmark
The Affiliated Hospital of Qingdao University

Recruiting

A Bioequivalence Trial of Irbesartan Tablets（0.15g） in Healthy Chinese Subjects

Bioequivalence | Irbesartan Tablets (0.15g/Tablet) | Under Fasted Condition | Under Fed Condition

China
Technische Universität Dresden

Completed

Characterization of Vascular Effects of Angiotensin II in Dorsal Human Hand Veins.

Healthy Subjects

Germany
Sanofi
Bristol-Myers Squibb

Completed

I PREVENT - Irbesartan In Hypertensive Diabetic Patients

Hypertension

Egypt
Sanofi
Bristol-Myers Squibb

Completed

I SAVE - Irbesartan in Mild to Moderate Hypertensive Patients

Hypertension

Egypt
Ligand Pharmaceuticals

Completed

A Study To Evaluate The Dose-Related Efficacy and Safety of PS433540 in Subjects With Hypertension

Hypertension

United States
Sanofi

Completed

Irbesartan-Hydrochlorothiazide Phase IV Study: Treatment of Hypertension in Chinese Population

Hypertension

China
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan/Hydrochlorothiazide (HCTZ) Combination Therapy for Patients With Moderate Hypertension

Hypertension

United States, Canada, Germany, Russian Federation, France
Travere Therapeutics, Inc.

Active, not recruiting

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX)

Focal Segmental Glomerulosclerosis

United States, Australia, Belgium, Croatia, Estonia, Germany, Hong Kong, Italy, Korea, Republic of, Poland, Portugal, Spain, Taiwan, United Kingdom, Argentina, Brazil, Canada, Czechia, Denmark, France, New Zealand, Sweden
Novartis

Completed

VALID: Study to Compare the Reduction of Predialysis Systolic Blood Pressure With Valsartan Compared to Irbesartan in Patients With Mild to Moderate Hypertension on Long-term Hemodialysis

Hypertension

Switzerland, Germany
Sanofi
Bristol-Myers Squibb

Completed

AMISH : Aprovel for Management of Isolated Systolic Hypertension

Hypertension

Korea, Republic of, Mexico, Taiwan, Thailand, Philippines, Chile, China, Indonesia
University Hospital, Grenoble
Institut National de la Santé Et de la Recherche Médicale, France

Terminated

Intermittent Hypoxia 2: Cardiovascular and Metabolism (IH2)

Hypoxia | Obstructive Sleep Apnea | Sleep Apnea

France
University of Magdeburg
Sanofi

Unknown

Irbesartan and Adhesion Molecules in AF (CREATIVE-AF)

Persistent Atrial Fibrillation

Germany
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Novartis

Completed

Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension

Essential Hypertension

Japan
Novartis Pharmaceuticals

Completed

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Hypertension

Sweden, United States, Peru, Russian Federation, Romania, Mexico, Panama, Spain, Denmark, Italy, Greece, South Africa, Canada, Argentina, Australia, Colombia, Finland, Taiwan
Assistance Publique - Hôpitaux de Paris

Recruiting

Impact of a Treatment With Angiotensin Receptor Blocker on Outcome After Acute Kidney Injury in Patients Discharged From the ICU. (START-or-NOT)

Acute Kidney Injury

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

Essential Hypertension

Japan
Aristotle University Of Thessaloniki

Withdrawn

Irbesartan Versus Amlodipine: The OBI Study (OBI)

Hypertension | Obesity

Greece
Sanofi

Completed

Evaluation of the Fixed-dose Combination of Irbesartan/Atorvastatin in Type 2 Diabetic Patients Diagnosed With Hyperlipidemia and Hypertension

Type 2 Diabetes Mellitus

Korea, Republic of
Hanmi Pharmaceutical Company Limited

Completed

Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia

Hypertension | Hyperlipidemia

Korea, Republic of
Alnylam Pharmaceuticals

Completed

A Study to Evaluate ALN-AGT01 in Patients With Hypertension

Hypertension

United Kingdom
Montefiore Medical Center
NCM USA

Completed

Diagnosis and Staging of Neuroendocrine Tumors (NETs) Utilizing 68Ga-DOTATOC PET/CT Scan

Neuroendocrine Tumors
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Completed

To Assess Allisartan Isoproxil/Amlodipine Tablets in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

Essential Hypertension

China
Hanmi Pharmaceutical Company Limited

Completed

Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension

Hypertension

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Hypertension | Ankle Edema

Netherlands

3

Subscribe